Predictors of erlotinib utilization and the impact of erlotinib use on overall survival in advanced, non-small cell lung cancer

Journal article

Peer reviewed

Jennifer L. Ersek, James Thomas Symanowski, Edward S. Kim, Swann Arp Adams, James R. Hébert and Jan Marie Eberth

Journal of clinical oncology, v 36(15_suppl), pp e18741-e18741

20 May 2018

Additional Links

Abstract only

6 Record Views

Title: Predictors of erlotinib utilization and the impact of erlotinib use on overall survival in advanced, non-small cell lung cancer
Creators: Jennifer L. Ersek - Levine Cancer Institute
James Thomas Symanowski - Levine Cancer Institute
Edward S. Kim - Levine Cancer Institute
Swann Arp Adams - University of South Carolina
James R. Hébert - Connecting Health Innovations (United States)
Jan Marie Eberth - University of South Carolina
Publication Details: Journal of clinical oncology, v 36(15_suppl), pp e18741-e18741
Resource Type: Journal article
Language: English
Academic Unit: Health Management and Policy
Web of Science ID: WOS:000442916006119
Other Identifier: 991021855271004721

Data related to this publication, from InCites Benchmarking & Analytics tool: